Abstract
Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that resides at the sites of at focal adhesions. The 125 kDa FAK protein is encoded by the FAK gene located on human chromosome 8q24. Structurally, FAK consists of an amino-terminal regulatory FERM domain, a central catalytic kinase domain, and a carboxy-terminal focal adhesion targeting domain. FAK has been shown to be an important mediator of cell adhesion, growth, proliferation, survival, angiogenesis and migration, all of which are often disrupted in cancer cells. Normal tissues have low expression of FAK, while primary and metastatic tumors significantly overexpress this protein. This review summarizes expression of FAK by immunohistochemical staining in different tumor types and presents several FAK inhibition therapy approaches.
Keywords: Adhesion, cancer, Focal Adhesion Kinase, inhibitor, metastasis, tumor, Breast Cancer, Hepatocellular Carcinoma, Acute Myeloid Leukemia, HBV, FRNK, Troglitazone, Neuroblastoma, IHC, EGFR
Anti-Cancer Agents in Medicinal Chemistry
Title: Focal Adhesion Kinase as a Cancer Therapy Target
Volume: 10 Issue: 10
Author(s): Vita M. Golubovskaya
Affiliation:
Keywords: Adhesion, cancer, Focal Adhesion Kinase, inhibitor, metastasis, tumor, Breast Cancer, Hepatocellular Carcinoma, Acute Myeloid Leukemia, HBV, FRNK, Troglitazone, Neuroblastoma, IHC, EGFR
Abstract: Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that resides at the sites of at focal adhesions. The 125 kDa FAK protein is encoded by the FAK gene located on human chromosome 8q24. Structurally, FAK consists of an amino-terminal regulatory FERM domain, a central catalytic kinase domain, and a carboxy-terminal focal adhesion targeting domain. FAK has been shown to be an important mediator of cell adhesion, growth, proliferation, survival, angiogenesis and migration, all of which are often disrupted in cancer cells. Normal tissues have low expression of FAK, while primary and metastatic tumors significantly overexpress this protein. This review summarizes expression of FAK by immunohistochemical staining in different tumor types and presents several FAK inhibition therapy approaches.
Export Options
About this article
Cite this article as:
M. Golubovskaya Vita, Focal Adhesion Kinase as a Cancer Therapy Target, Anti-Cancer Agents in Medicinal Chemistry 2010; 10 (10) . https://dx.doi.org/10.2174/187152010794728648
DOI https://dx.doi.org/10.2174/187152010794728648 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Roles of Tumor Microenvironment in Hepatocelluar Carcinoma
Current Cancer Therapy Reviews Peripheral TRPV1 Receptors As Targets for Drug Development: New Molecules and Mechanisms
Current Pharmaceutical Design Piceatannol Modulates Lung Epithelial Cellular Responses to Pseudomonas aeruginosa
Inflammation & Allergy - Drug Targets (Discontinued) New Drug Design for Gene Therapy - Taking Advantage of Introns
Letters in Drug Design & Discovery Therapeutic Applications of Crocus sativus L. (Saffron): A Review
The Natural Products Journal New Indications for Established Drugs: Combined Tumor-Stroma-Targeted Cancer Therapy with PPARγ Agonists, COX-2 Inhibitors, mTOR Antagonists and Metronomic Chemotherapy
Current Cancer Drug Targets Indoleamine 2,3-Dioxygenase in Materno-Fetal Interaction
Current Drug Metabolism Revealing Insights into Natural Products Against mcr-1-Producing Bacteria
Current Drug Targets Novel Agents Targeting Bioactive Sphingolipids for the Treatment of Cancer
Current Medicinal Chemistry The Sodium-Iodide Symporter
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Synthesis and In Vitro Anticancer Activity of Novel 2-((3-thioureido)carbonyl) phenyl Acetate Derivatives
Letters in Drug Design & Discovery Bcl-2 Inhibitors: Emerging Drugs in Cancer Therapy
Current Medicinal Chemistry Local Recurrence vs Radiotherapy-Induced Edema in Advanced Laryngeal Carcinoma: Is FDG PET/CT Up to the Challenge?
Current Molecular Imaging (Discontinued) Potentials and Challenges of Active Targeting at the Tumor Cells by Engineered Polymeric Nanoparticles
Current Pharmaceutical Biotechnology Cannabinoid System as a Potential Target for Drug Development in the Treatment of Cardiovascular Disease
Current Vascular Pharmacology The Molecular Machinery Regulating Apoptosis Signal Transduction and its Implication in Human Physiology and Pathophysiologies
Current Molecular Medicine Epidermal Growth Factor Receptor-Targeted Therapy of Colorectal Cancer with Panitumumab
Current Cancer Therapy Reviews Organ Preference of Cancer Metastasis and Metastasis-Related Cell Adhesion Molecules Including Carbohydrates
Cardiovascular & Hematological Disorders-Drug Targets Nanotechnology in Dentistry: Drug Delivery Systems for the Control of Biofilm-Dependent Oral Diseases
Current Drug Delivery Aldo-Keto Reductase Family 1 Member B1 Inhibitors: Old Drugs with New Perspectives
Recent Patents on Anti-Cancer Drug Discovery